The New Rules of Global Drug Development
Caidya Executive Chairman Lingshi Tan explains why capital discipline, early clinical execution, and global development strategy are becoming central to biotech success
False
Caidya Executive Chairman Lingshi Tan explains why capital discipline, early clinical execution, and global development strategy are becoming central to biotech success
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
False
False
August 21, 2026
5 min read
Former military intelligence officer Tony Page discusses what pharma can learn from early warning systems, decision cycles, and the discipline of intelligence
August 20, 2026
6 min read
From multiple sclerosis to AI-driven discovery, Daniel Vitt reflects on the future of drug development
August 19, 2026
5 min read
Can iPSC platforms deliver consistent, commercial-scale cell therapies for large patient populations?
August 18, 2026
10 min read
From collapsing legacy models to the rise of Chinese biotech, industry leaders are being forced to rethink how drugs are developed, funded, and brought to market
False
Affiliations:
Specialties:
Areas of Expertise: